Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease
Main finding · MALOResult — go to the resultHazard ratio 0.91 95% CI 0.78–1.07Authors' conclusion
GLP-1 RAs were associated with a potentially lower hazard for incident MALO and liver cirrhosis compared with SGLT-2 inhibitors in people with MASLD and type 2 diabetes
Study context
- Population
- People with MASLD and T2D, claims data from Germany (2005–2024)
- Participants
- 45,256 people
- Exposure
- GLP-1 RA vs SGLT2 inhibitors
- GLP-1 RAsn = 9,993
- SGLT-2 inhibitorsn = 35,263reference
- Outcome
- Major adverse liver outcomes (MALO)
- Follow-up
- median 4.3-year follow-up
Methodological detailsclaims data, matching weights, weighted Cox proportional hazard models
- Claims data
- Matching weights
- Weighted Cox proportional hazard models
Main finding
MALO
Hazard ratio
0.91
95% CI 0.78–1.07
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Major adverse liver outcomes (MALO), on-treatment approach · median 4.3-year follow-up
- HR, MALO (on-treatment)
- HR 0.78, 95% CI 0.58-1.03
MALO, restricted to hospital diagnoses in primary position · median 4.3-year follow-up
- HR, MALO (hospital diagnoses in primary position)
- HR 0.77, 95% CI 0.56-1.07
Liver cirrhosis · median 4.3-year follow-up
- HR, liver cirrhosis
- HR 0.88
Decompensation events · median 4.3-year follow-up
- HR, decompensation events
- HR 0.91
Hepatocellular carcinoma (HCC) · median 4.3-year follow-up
- HR, HCC
- HR 0.76
All-cause mortality · median 4.3-year follow-up
- No benefit for all-cause mortality; HR
- HR 1.04
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →